相关实验视频

Updated: Feb 17, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

在接受化疗的固体恶性瘤患者中,对SARS-CoV-2疫苗接种的长期细胞和幽默反应

Andrew Liu¹, Brian Necela², Zhuo Li³

¹Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, United States.

Frontiers in immunology

|February 16, 2026

概括

接受化疗的癌症患者最初对SARS-CoV-2疫苗呈现较低的抗体反应,但随着时间的推移,他们产生了持久的细胞和幽默免疫力. 这导致了与健康个体相比,类似的COVID-19感染和住院率.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
疫苗学疫苗学疫苗学

背景情况:

在接受化疗的癌症患者中,对SARS-CoV-2疫苗接种的免疫反应尚不清楚.
现有的研究往往忽视了细胞免疫力,主要关注抗体反应.
癌症患者在接种疫苗后可能会出现免疫反应减弱的情况.

研究的目的:

评估在接受化疗的固体瘤患者中对SARS-CoV-2疫苗接种的幽默和细胞免疫反应.
将这些反应与健康个体的一年时间内的反应进行比较.
为了评估免疫记忆的耐用性和大小.

主要方法:

18岁以上的注册患者愿意接受SARS-CoV-2疫苗.
使用抗SARS-CoV-2免疫测试来检测抗体 (核囊体,尖端蛋白).
采用人类IFN-γ光斑试验来测量抗原特异性T细胞反应.
使用曼-惠特尼和费舍尔精确测试,比较癌症患者和健康对照者的数据.

主要成果:

最初,96%的癌症患者和100%的健康人群在接种疫苗后表现出积极的幽默反应.
癌症患者最初的IgG抗体峰值较低,但这种差异在6-12个月后得到解决.
在所有时间点 (1-3,6,12个月) 中,癌症患者和健康个体之间的抗原特异性T细胞反应是可比的.
尽管癌症患者的COVID风险得分较高,但在COVID-19感染或住院率中没有发现显著差异.

结论:

接受化疗的固体瘤患者在SARS-CoV-2疫苗接种后发展出强大的长期细胞和幽默免疫力.
癌症患者的初始抗体反应缺陷在6-12个月内被克服.
疫苗接种在癌症患者和健康人群中提供了与COVID-19感染和住院治疗相似的保护.

关键词:

在SARS-CoV-2疫苗中使用.化疗化疗是一种化学疗法.对常规疫苗的幽默和细胞反应.的大小和耐久性.患有固体瘤的患者.

更多相关视频

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Vaccinations

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Humoral Immune Responses

Humoral Immune Responses

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...